DANIELLE ORGAN PETERS

View full entity profile (contributions, contracts, SEC) →

Lobbying Income

$5K

Filings

200

Unique Clients

Active Period

2009–2014

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2014	$5,000	10	3
2013	—	15	4
2012	—	23	7
2011	—	38	11
2010	—	49	13
2009	—	65	15

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
NANOTHERAPEUTICS INC	$5,000	6	2013–2014
FABIANI & COMPANY ON BEHALF OF TRIUS THERAPEUTICS	—	18	2009–2012
FABIANI & COMPANY ON BEHALF OF 3-V BIOSCIENCES	—	8	2009–2010
FABIANI & COMPANY ON BEHALF OF VAXINNATE	—	4	2009
FABIANI & COMPANY ON BEHALF OF MEDRAD INC.	—	17	2009–2012
FABIANI & COMPANY ON BEHALF OF NANOTHERAPEUTICS INC.	—	15	2009–2011
FABIANI & COMPANY ON BEHALF OF THEROX, INC.	—	10	2009–2011
FABIANI & COMPANY ON BEHALF OF CRESTONE INC.	—	3	2009–2010
FABIANI & COMPANY ON BEHALF OF THERAPURE BIOPHARMA	—	9	2009–2012
FABIANI & COMPANY ON BEHALF OF PLANET BIOTECHNOLOGY INC.	—	5	2009
FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS	—	17	2009–2012
FABIANI & COMPANY ON BEHALF OF ARCA BIOPHARMA INC	—	15	2009–2012
FABIANI & COMPANY ON BEHALF OF MEDICAGO	—	14	2009–2012
THE CONAFAY GROUP, LLC ON BEHALF OF MEDICAGO	—	7	2013–2014
FABIANI & COMPANY ON BEHALF OF VARIATION BIOTECHNOLOGIES	—	9	2009–2011
FABIANI & COMPANY ON BEHALF OF SCYNEXIS	—	11	2009–2011
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP	—	9	2013–2014
THE CONAFAY GROUP ON BEHALF OF ZIOPHARM ONCOLOGY, INC.	—	3	2013
FABIANI & COMPANY ON BEHALF OF CONCERT PHARMACEUTICALS	—	14	2010–2012
FABIANI & COMPANY ON BEHALF OF OCERA THERAPEUTICS INC.	—	6	2009–2010

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
Defense, Dept of (DOD)	87
SENATE	80
HOUSE OF REPRESENTATIVES	78
Natl Institutes of Health (NIH)	47
Health & Human Services, Dept of (HHS)	37
Veterans Affairs, Dept of (VA)	19
Commerce, Dept of (DOC)	3
Energy, Dept of	3
Natl Aeronautics & Space Administration (NASA)	2
Defense Advanced Research Projects Agency (DARPA)	1

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	93
Defense	Defense	92
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	50
Budget/Appropriations	Budget/Appropriations	29
Copyright/Patent/Trademark	Copyright/Patent/Trademark	20
Veterans	Veterans	18
Pharmacy	Pharmacy	3
Trade (domestic/foreign)	Trade (domestic/foreign)	3

Bills Explicitly Cited (21)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3590110th Congress

American Middle Class Tax (AMT) Relief Act of 2007

2010 · third_quarter · Client: FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 3590 Patient Protection and Affordable Care Act, Therapeutic Tax Credit provision

Client expense: — · Firm income: —

Matched citations: HR 3590

H.R. 3590110th Congress

American Middle Class Tax (AMT) Relief Act of 2007

2010 · second_quarter · Client: FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 3590 Patient Protection and Affordable Care Act, Therapeutic Tax Credit provision

Client expense: — · Firm income: —

Matched citations: HR 3590

H.R. 3590110th Congress

American Middle Class Tax (AMT) Relief Act of 2007

2010 · first_quarter · Client: FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 3590 Patient Protection and Affordable Care Act, Therapeutic Tax Credit provision

Client expense: — · Firm income: —

Matched citations: HR 3590

S. 515111th Congress

Patent Reform Act of 2009

2009 · fourth_quarter · Client: FABIANI & COMPANY ON BEHALF OF MEDRAD INC.

Open original LDA filing ↗

Cited source text and reported amounts

S 515 Patent Reform Act, provisions relating to apportionment of damages

Client expense: — · Firm income: —

Matched citations: S 515

Show 17 more cited filings

S. 515111th Congress

Patent Reform Act of 2009

2009 · fourth_quarter · Client: FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

S. 515 Patent Reform Act of 2009

Client expense: — · Firm income: —

Matched citations: S. 515

S. 515111th Congress

Patent Reform Act of 2009

2009 · third_quarter · Client: FABIANI & COMPANY ON BEHALF OF MEDRAD INC.

Open original LDA filing ↗

Cited source text and reported amounts

S 515 Patent Reform Act, provisions relating to apportionment of damages

Client expense: — · Firm income: —

Matched citations: S 515

S. 515111th Congress

Patent Reform Act of 2009

2009 · third_quarter · Client: FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

S. 515 Patent Reform Act of 2009

Client expense: — · Firm income: —

Matched citations: S. 515

S. 515111th Congress

Patent Reform Act of 2009

2009 · second_quarter · Client: FABIANI & COMPANY ON BEHALF OF MEDRAD INC.

Open original LDA filing ↗

Cited source text and reported amounts

S 515 Patent Reform Act, provisions relating to apportionment of damages

Client expense: — · Firm income: —

Matched citations: S 515

S. 515111th Congress

Patent Reform Act of 2009

2009 · second_quarter · Client: FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

S. 515 Patent Reform Act of 2009

Client expense: — · Firm income: —

Matched citations: S. 515

S. 515111th Congress

Patent Reform Act of 2009

2009 · first_quarter · Client: FABIANI & COMPANY ON BEHALF OF MEDRAD INC.

Open original LDA filing ↗

Cited source text and reported amounts

S.515 Patent Reform Act of 2009, Provisions relating to apportionment of damages

Client expense: — · Firm income: —

Matched citations: S.515

S. 515111th Congress

Patent Reform Act of 2009

2009 · first_quarter · Client: FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

S. 515 Patent Reform Act of 2009 Provisions relating to apportionment of damages

Client expense: — · Firm income: —

Matched citations: S. 515

S. 515111th Congress

Patent Reform Act of 2009

2009 · first_quarter · Client: FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

S.515 Patent Reform Act of 2009

Client expense: — · Firm income: —

Matched citations: S.515

S. 515111th Congress

Patent Reform Act of 2009

2009 · first_quarter · Client: FABIANI & COMPANY ON BEHALF OF MEDRAD INC.

Open original LDA filing ↗

Cited source text and reported amounts

Reimbursement for medical imaging procedures FY2010 Energy & Water Appropriations Act, funding for cardiovascular imaging research S. 515 Patent Reform Act of 2009

Client expense: — · Firm income: —

Matched citations: S. 515

S. 515111th Congress

Patent Reform Act of 2009

2009 · first_quarter · Client: FABIANI & COMPANY ON BEHALF OF MEDRAD INC.

Open original LDA filing ↗

Cited source text and reported amounts

Reimbursement for medical imaging procedures FY2010 Energy & Water Appropriations Act, funding for cardiovascular imaging research S. 515 Patent Reform Act of 2009

Client expense: — · Firm income: —

Matched citations: S. 515

S. 515111th Congress

Patent Reform Act of 2009

2009 · first_quarter · Client: FABIANI & COMPANY ON BEHALF OF MEDRAD INC.

Open original LDA filing ↗

Cited source text and reported amounts

Reimbursement for medical imaging procedures FY2010 Energy & Water Appropriations Act, funding for cardiovascular imaging research S. 515 Patent Reform Act of 2009

Client expense: — · Firm income: —

Matched citations: S. 515

S. 515111th Congress

Patent Reform Act of 2009

2009 · first_quarter · Client: FABIANI & COMPANY ON BEHALF ALNYLAM PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts